Current Report Filing (8-k)
19 December 2017 - 8:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 18, 2017 (December 15, 2017)
ALLERGAN PLC
(Exact Name
of Registrant as Specified in Charter)
|
|
|
|
|
Ireland
|
|
001-36867
|
|
98-1114402
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Clonshaugh Business and Technology Park
Coolock, Dublin, D17 E400, Ireland
(Address of Principal Executive Offices)
(862)
261-7000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c)
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compulsory Arrangements of Certain Officers
|
On December 18, 2017, Allergan plc (the Company) announced that on December 15, 2017, Robert Stewart informed the
Company of his intention to resign as Chief Operating Officer, effective
mid-January
2018, to become President and Chief Executive Officer of Amneal Pharmaceuticals LLC starting January 25, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Dated: December 18, 2017
|
|
|
|
Allergan plc
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ A. Robert D. Bailey
|
|
|
|
|
Name:
|
|
A. Robert D. Bailey
|
|
|
|
|
Title:
|
|
Chief Legal Officer and Corporate Secretary
|
Allergan Plc Prfd A (NYSE:AGNPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allergan Plc Prfd A (NYSE:AGNPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allergan Plc Prfd A (New York Stock Exchange): 0 recent articles
More Allergan Plc News Articles